Ind-Swift Laboratories Ltd (INDSWFTLAB) is currently trading at 346.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Ind-Swift Laboratories is a Chandigarh‑based pharmaceutical company that has transformed from an API manufacturer into a focused finished dosage formulation (FDF) manufacturer and CDMO partner, commercialising agreements with global generic majors and expanding its regulated‑market filings and exports. Q1 FY27 showed a sharp operational turnaround: operating income grew 21.2% year‑on‑year to ₹186.08 crore, EBITDA expanded 2.85x to ₹33.32 crore with margin improvement to 17.91%, and PAT excluding exceptionals doubled to ₹24.68 crore, signalling meaningful margin recovery and execution on strategic priorities. The company commercialised CDMO deals with Viatris, Manx and Arrotex during the quarter; these are expected to deliver incremental revenue of roughly ₹200–₹220 crore across FY27‑FY29, although only ~₹5–6 crore was booked in Q1 as initial shipments began and scale will occur across coming quarters. Ind-Swift is investing in regulated‑market capability and capacity: dossiers filed rose to 2,100+, product registrations to 850+, and a planned Samba facility upgrade to EU‑GMP and PIC/S standards is underway, supported by a ₹250 crore capex plan to be deployed over the next 2–2.5 years. The company’s strong cash position following the earlier API slump sale funds capex and strategic optionality; management expects exports to be the primary growth engine while domestic business provides stable cash generation and brand/registration expansion supports margin durability.

Over the past 52 weeks, Ind-Swift Laboratories Ltd has traded between a low of ₹87.00 and a high of ₹426.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Ind-Swift Laboratories Ltd has a market capitalization of approximately 3,080.18. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Ind-Swift Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 36.95 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 3,080.18 Cr, Ind-Swift Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Ind-Swift Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Ind-Swift Laboratories Ltd is 36.95. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Ind-Swift Laboratories reported Q2 FY27 operating EBITDA of Rs 42.33 crore. The detailed quarterly table compared this with Rs 8.55 crore in Q2 FY26, representing a 4.95-times increase.

The board meeting to consider unaudited results for the quarter and half year ended September 30, 2026 is scheduled for October 29, 2026.

Standalone PAT excluding exceptional items was ₹24.68 crore in Q1 FY27, up 2.04 times year-on-year from ₹8.12 crore in Q1 FY26.

Standalone PAT excluding exceptional items was ₹24.68 crore in Q1 FY27, up 2.04 times year-on-year from ₹8.12 crore.